USA flag logo/image

An Official Website of the United States Government

Management of Brain Tumor Treatment with Tumor Morphometrics in Magnetic…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85441
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
CA128188
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PRISM CLINICAL IMAGING INC.
890 Elm Grove Rd. Ste. 215 Elm Grove, WI 53122-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Management of Brain Tumor Treatment with Tumor Morphometrics in Magnetic Resonanc
Agency: HHS
Contract: 1R43CA128188-01
Award Amount: $200,619.00
 

Abstract:

DESCRIPTION (provided by applicant): Radiology has traditionally relied upon qualitative assessment of tumor growth to guide therapeutic decision-making. The adoption of quantitative techniques such as WHO and RECIST guidelines in radiology has been slow due to multiple factors, including the workload and inter-operator variability associated with manual measurement, the complexity and pitfalls of automated techniques, and the many inherent sources of variability in medical imaging making longitudinal comp arison difficult. We will develop, design and evaluate a semi- automated morphometrics system for quantification of tumors in the brain. The input to our system will be multiple images from magnetic resonance imaging (MRI) systems, particularly post-contra st T1 studies. The final product will be a modular extension to our FDA-cleared Prism View(tm) software package, compatible with MRI systems currently used for brain imaging. We will demonstrate feasibility in Phase I by developing means for geometrical re gistration and intensity standardization in imaging protocols, collecting data to document intra-patient and intra- and inter-reader variability, and evaluating our system in a study of a small number of subjects. In Phase II, we will further refine algori thms based upon Phase I findings and evaluate our system in a much larger cohort of subjects to more rigorously evaluate accuracy and precision in sizing of tumors. If successful, greater confidence will be achieved in following tumor changes over time, an d this should translate into more rapid understanding of the efficacy of medical treatment or management of brain tumors. Our focus is on 2D and 3D tumor geometry, not on tumor composition. However, the existing product line (Prism) already facilitates com bination and viewing of functional and physiologic information including MR spectroscopy and MR perfusion studies, and this information will be readily superposed upon the regions of interest delineated in anatomical imagery.

Principal Investigator:

James Reuss
4147271930
JAMESREUSS@KYRONCLINICAL.COM

Business Contact:

Michael Schmainda
jreuss@prismclinical.com
Small Business Information at Submission:

PRISM CLINICAL IMAGING INC.
PRISM CLINICAL IMAGING, INC. 851 S. 70th St., Suite 103 West Allis, WI 53214

EIN/Tax ID: 120198551
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No